{"effect":{"id":"vomiting","name":"Vomiting","severity":"moderate","description":"Actively throwing up, beyond just feeling nauseous. More severe than nausea and often co-occurs with it. Usually dose-dependent.","clinicalRates":{"low":0.03,"medium":0.05,"high":0.08},"clinicalRatesNote":"A fixed reference table dated 2026-04-12, not derived from this corpus and carrying no per-effect citation of its own — see `sources` on ?q=effect&id=<id> for what was recorded behind each effect. It reaches published numbers two ways. (1) As the sole clinical base for an effect with no eligible corpus rate point — exactly the effects whose pooled corpus estimate is null (corpusClinical here, rateBase.clinical.pooledEstimate on the per-effect endpoint); the predictor marks these isFallback: true. (2) Since 2026-08-28, as a dose-tier rescale ratio applied to the corpus's OWN pooled rate wherever that tier's pooled clinical records are mostly dose-untagged; isFallback stays false in that case, and the predictor's clinical.basis states both endpoints and the dose-tag denominator while clinical.pooledPercentage carries the corpus rate before any adjustment. Full per-source detail: rateBase.clinical via ?q=effect&id=<id>. WITHDRAWN 2026-09-03 (decision literature-fallback-clinical-rate-2026-08-28, option c) for emotional_blunting only: this table had no rate-stating source at all for it, so its clinicalRate fields are null here and its predictor track carries `available: false` with no percentage — see clinicalRatesWithdrawn on ?q=effect&id=emotional_blunting. RE-SOURCED 2026-09-03 (same decision, option b) for fatigue only: its three tier values are one figure, 0.11, from the FDA Wegovy prescribing information revised 06/2026 (Table 3: fatigue incl. asthenia 11% on 2.4 mg, N=2,116, vs 5% placebo, N=1,261; URL in its sources) — the label reports no per-dose-tier rate, so no gradient is published for it, and it is a semaglutide figure applied at every dose tier regardless of molecule, as this whole table is. RE-SOURCED 2026-09-04 (decision pancreatitis-hairloss-dizziness-triple-derivation-2026-09-03) for hair_loss, dizziness and pancreatitis: their 2026-04-12 triples (1–3%, 2–5%, 0.5–1.2%) had no recorded derivation and their cited trial pages state no such figures; each is now one value at every tier from the same FDA Wegovy label — hair_loss 0.03 (Table 3: 3% on 2.4 mg, N=2,116, vs 1% placebo), dizziness 0.08 (Table 3: 8% vs 4%), and pancreatitis 0.002, which is NOT a proportion of patients like every other value in this table but the label's incidence RATE of 0.2 acute-pancreatitis cases per 100 patient-years of Wegovy exposure (4 adjudicated cases vs 1 on placebo, section 5) — read it with that unit. Figures served before 2026-09-04 for these three effects should not be cited.","confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","modifiers":{"femaleFactor":1.3,"ageFactor65plus":1.1,"giHistoryFactor":1.5,"diabetesFactor":0.9,"firstMonthFactor":2.5},"modifiersNote":"Odds ratios hand-coded at the 2026-04-12 seed with no per-modifier citation recorded — treat each as an expert-coded prior, not a sourced estimate. The FDR-corrected empirical estimator runs daily but no effect yet meets its evidence bar (model config v2 — its one post-seed change, 2026-09-04, re-sourced four static base rates by hand; zero empirical modifiers applied). See ?q=help for the full methodology note.","reportingFrequency":{"mentions":11,"distinctReports":26,"sharePct":42.3,"platforms":["reddit.com","drugs.com"],"note":"Share of distinct community reports (one row per source URL) that mention this effect. Counts only reports hosted on the community platform itself, and — corrected 2026-08-29 — only Reddit posts from the GLP-1, weight-management and diabetes subreddits we collect from: the scraper's subreddit restriction was not holding, and 159 of the previous 185 reports were posts matched on a symptom word in unrelated communities (r/gallbladders, r/AskDocs, r/pregnant). News-aggregator results are excluded, see platforms. The remaining base is small and cannot currently grow (Reddit has blocked our collector since 2026-05-28), so read every share with its distinctReports denominator. Not an incidence rate; not comparable to clinicalRates."},"userReportedSeverity":"Users who experience vomiting say it typically happens after eating too much or too quickly. Most learn to adapt portion sizes within 1-2 weeks.","onsetDays":"Not stated by any clinical source on file.","durationWeeks":"Not stated by any clinical source on file.","managementTip":"Eat very small portions slowly. Avoid lying down after eating. If vomiting is persistent or severe, contact your doctor — dose reduction may help.","sources":[{"name":"STEP-1 Trial (Wilding et al., NEJM 2021)","type":"clinical","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","weight":0.3},{"name":"Reddit r/Ozempic & r/Mounjaro vomiting threads (2024-2026)","type":"user_report","weight":0.4},{"name":"SURMOUNT-1 Trial (Jastreboff et al., NEJM 2022)","type":"clinical","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","weight":0.3}]},"dataPointCount":188,"rateBase":{"note":"Only externally citable, non-duplicated rates support an estimate. Shares of spontaneous adverse-event reports (FAERS) are reported separately — they are not incidence. A source marked rateKind: \"serious_ae\" states a rate from a trial registry's SERIOUS adverse-events table for a term posted in no other table of the same arm — a real stated figure, but a floor on all-cause incidence, since the registry lists non-serious events only above the trial's reporting threshold.","clinical":{"statedRates":25,"distinctSources":15,"sourceEntries":15,"pooledEstimate":{"ratePct":10,"ciLowPct":0,"ciHighPct":72,"statedRates":25,"distinctSources":15,"sourceEntries":15,"seriousAeSources":0,"rateKindNote":"","rateKindNoteNl":"","confidence":"high","sourceDiversity":"high"},"confidenceNote":"`sourceDiversity` (formerly `confidence`, kept as a deprecated alias with the same value) measures SOURCE DIVERSITY, not precision: it is derived only from distinctSources (≤1 very_low, ≤3 low, ≤9 moderate, ≤24 high, ≥25 very_high) and is computed without reference to the confidence interval. It can read `moderate` on an estimate whose interval spans nearly the whole range — always read ciLowPct/ciHighPct alongside it, and treat a wide interval as the binding statement about how well we know the rate.","seriousAeSources":0,"sources":[{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Vomiting","url":"https://clinicaltrials.gov/study/NCT05086445#adverse-events","rate":0.4,"sampleSize":10,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Vomiting","url":"https://clinicaltrials.gov/study/NCT03929744#adverse-events","rate":0.584,"sampleSize":6,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period  — Vomiting","url":"https://clinicaltrials.gov/study/NCT05936138#adverse-events","rate":0.167,"sampleSize":6,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Vomiting","url":"https://clinicaltrials.gov/study/NCT05548647#adverse-events","rate":0.347,"sampleSize":72,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide  — Vomiting","url":"https://clinicaltrials.gov/study/NCT04596631#adverse-events","rate":0.197,"sampleSize":66,"rateKind":"incidence"},{"name":"PubMed — A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic ","url":"https://pubmed.ncbi.nlm.nih.gov/33185364/","rate":0.15,"sampleSize":82,"rateKind":"incidence"},{"name":"PubMed — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.","url":"https://pubmed.ncbi.nlm.nih.gov/34170647/","rate":0.08,"sampleSize":1879,"rateKind":"incidence"},{"name":"PubMed — Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.","url":"https://pubmed.ncbi.nlm.nih.gov/41445996/","rate":0.07,"sampleSize":null,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Participants With Obes — Vomiting","url":"https://clinicaltrials.gov/study/NCT04184622#adverse-events","rate":0.112,"sampleSize":636,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Semaglutide Effects on Heart Disease and Stroke in Patients  — Vomiting","url":"https://clinicaltrials.gov/study/NCT03574597#adverse-events","rate":0.065,"sampleSize":8803,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — STEP 1: Research Study Investigating How Well Semaglutide Wo — Vomiting","url":"https://clinicaltrials.gov/study/NCT03548935#adverse-events","rate":0.246,"sampleSize":1306,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — Research Study Investigating How Well Semaglutide Works in P — Vomiting","url":"https://clinicaltrials.gov/study/NCT03552757#adverse-events","rate":0.174,"sampleSize":403,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) Compared With Dulaglutide — Vomiting","url":"https://clinicaltrials.gov/study/NCT04255433#adverse-events","rate":0.105,"sampleSize":6647,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of LY3437943 in Participants Who Have Obesity or Are — Vomiting","url":"https://clinicaltrials.gov/study/NCT04881760#adverse-events","rate":0.13,"sampleSize":69,"rateKind":"incidence"},{"name":"ClinicalTrials.gov results — A Study of Orforglipron in Adult Participants With Obesity o — Vomiting","url":"https://clinicaltrials.gov/study/NCT05872620#adverse-events","rate":0.231,"sampleSize":321,"rateKind":"incidence"}],"excluded":{"spontaneous_report_share":7,"no_rate":34,"seed_unverified":6},"usesPublishedFallback":false},"community":{"statedRates":0,"distinctSources":0,"sourceEntries":0,"excluded":{"no_rate":111,"seed_unverified":4,"aggregator_result":1},"usesPublishedFallback":true},"spontaneousReportShares":[{"source":"FDA FAERS — semaglutide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","shareOfReports":0.091,"reports":7479},{"source":"FDA FAERS — tirzepatide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"tirzepatide\"","shareOfReports":0.047,"reports":5685},{"source":"FDA FAERS — liraglutide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"liraglutide\"","shareOfReports":0.08,"reports":3447},{"source":"FDA FAERS — dulaglutide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"dulaglutide\"","shareOfReports":0.053,"reports":5413},{"source":"FDA FAERS — exenatide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"exenatide\"","shareOfReports":0.046,"reports":4346},{"source":"FDA FAERS — lixisenatide — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"lixisenatide\"","shareOfReports":0.021,"reports":72},{"source":"FDA FAERS — orforglipron — VOMITING","url":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"orforglipron\"","shareOfReports":0.065,"reports":75}]},"dataPointsBySource":{"clinical":65,"regulatory":7,"user_report":79,"news":37},"sampleDataPoints":[{"sourceName":"Reddit r/WegovyWeightLoss — Throwing up occasionally but consistently","sourceType":"user_report","sourceUrl":"https://reddit.com/r/WegovyWeightLoss/comments/1sel2x4/throwing_up_occasionally_but_consistently/","extractedRate":null,"extractedSeverity":"mild","extractedSampleSize":null,"extractionConfidence":"high","scrapedAt":"2026-04-07T04:00:41.380Z"},{"sourceName":"Reddit r/WegovyWeightLoss — Throwing up occasionally but consistently","sourceType":"user_report","sourceUrl":"https://reddit.com/r/WegovyWeightLoss/comments/1sel2x4/throwing_up_occasionally_but_consistently/","extractedRate":null,"extractedSeverity":"mild","extractedSampleSize":null,"extractionConfidence":"high","scrapedAt":"2026-04-07T04:00:42.984Z"},{"sourceName":"Reddit r/WegovyWeightLoss — Throwing up occasionally but consistently","sourceType":"user_report","sourceUrl":"https://reddit.com/r/WegovyWeightLoss/comments/1sel2x4/throwing_up_occasionally_but_consistently/","extractedRate":null,"extractedSeverity":"mild","extractedSampleSize":1,"extractionConfidence":"high","scrapedAt":"2026-04-07T04:00:45.728Z"},{"sourceName":"Reddit r/WegovyWeightLoss — Throwing up occasionally but consistently","sourceType":"user_report","sourceUrl":"https://reddit.com/r/WegovyWeightLoss/comments/1sel2x4/throwing_up_occasionally_but_consistently/","extractedRate":null,"extractedSeverity":"mild","extractedSampleSize":null,"extractionConfidence":"high","scrapedAt":"2026-04-07T04:00:47.373Z"},{"sourceName":"FDA FAERS — semaglutide — VOMITING","sourceType":"regulatory","sourceUrl":"https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:\"semaglutide\"","extractedRate":0.091,"extractedSeverity":null,"extractedSampleSize":82377,"extractionConfidence":"high","scrapedAt":"2026-04-07T04:00:49.876Z"}],"lastUpdated":"2026-09-10"}